跳至主要内容
临床试验/DRKS00017043
DRKS00017043招募中不适用

Potential influence of coagulation inhibitionon the perception of fear or aggressiveness

niversitätsklinik für Kardiologie und Angiologie0 个研究点目标入组 25 人开始时间: 2019年3月28日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
25

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 Years 至 80 Years(—)
性别
All

入选标准

  • Treatment group: Patients receiving dabigatran under one of the approved indications, e.g. non-valvular atrial fibrillation, thrombosis, pulmonary embolism or control group: Patients who, after clarifying questionable cardiac arrhythmias, do not require further drug or pacemaker treatment

排除标准

  • a) contraindications for dabigatran, e.g. Hypersensitivity to the active substance or to any of the excipients, severe renal insufficiency (creatinine clearance [CrCl] <30 ml / min), acute clinically relevant bleeding, organ damage increasing the risk of bleeding, spontaneous or pharmacological limitation of haemostasis, severe liver disease, concomitant systemically administered ketoconazole, cyclosporin, itraconazole or tacrolimus; Pat. With artificial heart valves.
  • b) Severe infections, trauma, tumors or terminal diseases that affect the brain.
  • c) Lack of consent.

研究者

发起方
niversitätsklinik für Kardiologie und Angiologie

相似试验